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Commensal microorganisms influence malignant progression by altering systemic inflammation. New data
from two groups (Ve´tizou et al., 2015; Sivan et al., 2015) indicate that the abundance of specific commensal
bacterial species enhances the anti-cancer activity of immune checkpoint inhibitors.Humans co-exist in a symbiotic relation-
ship with trillions of bacteria, viruses,
and fungi that populate the intestine,
skin, and upper respiratory and genitouri-
nary tracts. Technological advances have
unveiled that the normal flora of humans is
remarkably complex in that its compo-
nents outnumber human cells at a ratio
of 10:1. The intestine alone harbors up to
1,000 commensal bacterial species (Tud-
denham and Sears, 2015), mostly from
four major lineages (termed phyla): Pro-
teobacteria, Firmicutes, Actinobacteria,
and Bacteroidetes. Variations in the
composition of the bacterial flora have
been associated with metabolic changes
and obesity, as well as inflammation,
autoimmunity, and infectious diseases.
Studies with germ-free mice have shown
that forging a robust immune system
and a broad repertoire of T cell receptors
requires colonization by commensal mi-
croorganisms. The role of the microbiota
in the progression of extra-intestinal tu-mors, however, has only emerged in the
last 2 years.
Commensal bacteria have been found
to influence distal malignant evolution
by modulating systemic tumor-promoting
inflammation and, subsequently, the
magnitude of T-cell-dependent anti-tu-
mor immunity (Rutkowski et al., 2015). In
this study, tumor growth depended upon
host commensal microbes and was inde-
pendent of measurable bacterial translo-
cation. Intrinsic differences in some bac-
terial genera, such as Bacteroides, were
identified in co-housed mice that devel-
oped tumors at different growth rates in
a toll-like receptor 5 (TLR5)-dependent
manner (Rutkowski et al., 2015). How-
ever, the abundance of segmented fila-
mentous bacteria (SFBs), an obvious
target identified to drive interleukin-17
(IL-17) production and autoimmunity in
tumor-free mice (Ivanov et al., 2009;
Sano et al., 2015), was unchanged in
mice showing TLR5-dependent acceler-ated malignant progression. Therefore,
changes in the equilibrium between
commensal microbial communities (or
dysbiosis) influence the tumor growth
distally from places of bacterial coloniza-
tion. Elegant independent studies have
also demonstrated that the effectiveness
of immunotherapy against different tu-
mors also requires the presence of
commensal bacteria (Iida et al., 2013; Vi-
aud et al., 2013). However, understanding
how the repertoire of commensal mi-
crobes can be specifically manipulated
to synergize with available anti-cancer in-
terventions has remained elusive.
In a recent issue of Science, data from
two groups demonstrate how individual
bacterial species can be used to enhance
the effectiveness of immune checkpoint
inhibitors. Ve´tizou et al. (2015) and Sivan
et al. (2015) independently demonstrate
that the abundance of distinct species
fromthephylumBacteroidetesanddistinct
genera from the phylum Actinobacteria iscember 15, 2015 ª2015 Elsevier Inc. 1037
Figure 1. Commensal Microbiota Enhance Therapeutic Response to Checkpoint Blockade
Anti-CTLA-4 blockade is most efficacious in the presence of B. fragilis, whose cell-wall peptidoglycans
activate dendritic cells to produce IL-12, enhancing Th1 cell responses and boosting endogenous anti-
tumor immunity. Anti-PD-L1 therapy is enhanced through the addition of Bifidobacterium, resulting in
activated DCs and enhanced anti-tumor immune responses.
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CTLA-4 and PD-L1 inhibition, respectively
(Figure 1).
Ve´tizou and colleagues demonstrate
that an intact enteric flora is required for
the effectiveness of CTLA-4 blockers
against various extra-intestinal tumors in
mice. Supporting previous reports,
CTLA-4 inhibitors caused colitis by
inducing apoptosis of intestinal epithelial
cells. The authors found that enteric
disruption was associated with a change
in microbial content, including overrepre-
sentation of the order Clostridiales at the
expense of Bacteroidales and Burkhol-
deriales. When mice were depleted of
commensal bacteria with broad-spec-
trum antibiotics and recolonized with
Bacteroides species that were differen-
tially represented after CTLA-4 blockade,
the authors found that Bacteroides the-
taiotaomicron (Bt), Burkholderia cepacia
(Bc), and Bacteroides fragilis (Bf), but not
other bacterial species, restored anti-
cancer responses to anti-CTLA-4. Mech-
anistically, anti-tumor immunity elicited
by anti-CTLA-4 depended on lamina pro-
pia dendritic cell (DC) recognition and
processing of Bf capsular polysacharides,
resulting in IL-12 secretion and, subse-1038 Immunity 43, December 15, 2015 ª201quently, induction of Bf-specific T helper
1 (Th1) cell responses. Furthermore, the
authors were able to demonstrate that
transfer of Bf-specific Th1 cells from
CTLA-4-treated mice into tumor-bearing
recipients significantly impeded tumor
growth. Although the exact mechanism
of Bf-mediated tumor regression was
not known, Ve´tizou et al. demonstrated
the clinical relevance of their findings by
corresponding alterations in the composi-
tion of enteric bacteria isolated from pa-
tients treated with the CTLA-4 inhibitor
ipilimumab to the frequencies of Th1
T cells isolated from peripheral blood.
The authors demonstrated that patients
with metastatic melanoma clustered into
three groups (A–C) according to the pre-
dominance of certain bacterial species
and observed that the composition of
bacteria in patients from group B shifted
toward the composition of group C after
ipilimumab treatment. When the authors
used feces derived from patients origi-
nating from each of these three clusters
to reconstitute germ-free mice, it became
clear that tumor-bearing mice trans-
planted with the feces derived from group
C effectively responded to CTLA-4
blockade. Subsequent molecular analysis5 Elsevier Inc.unveiled that responding mice showed
fecal enrichment of immunogenic Bf (or
the related species Bacteroides thetaio-
taomicron) and that tumor size negatively
correlated with the abundance of Bf.
Paradoxically, transplantation of immuno-
genic Bc or Bf reduced the deterioration
of the enteric mucosa, thus segregating
their role in immunotherapeutic effective-
ness from that in toxicity.
Expanding on previous studies under-
scoring the differences in the composition
of enteric bacteria and subsequent T cell
responses in mice from different pro-
viders (Ivanov et al., 2009), Sivan and
colleagues found that growth of trans-
plantable SIY antigen+ B16 melanomas
was faster in Taconic mice than in mice
from the Jackson Laboratory. T-cell-
dependent differences in tumor growth
could be restored by co-housing or
through oral gavage of fecal material
from the opposite strain, supporting pre-
vious studies showing that anti-tumor
immunity depends on the composition
on commensal bacteria (Rutkowski
et al., 2015). Although differences in the
effectiveness of PD-L1 blockers were
observed between tumor-bearing mice
from both providers, the combination of
PD-L1 neutralization and oral administra-
tion of fecal materials from Jackson
Laboratory mice induced superior tu-
mor-specific T cell responses, along with
corresponding delays in tumor growth, in
Taconic mice. The effectiveness of trans-
ferring fecal materials from Jackson mice
was not due to differences in regulatory
T (Treg) cell frequencies within tumor
beds. By analyzing the composition of
enteric microflora in Taconic mice trans-
planted with fecal materials from Jackson
animals, the authors identified specific
bacteria associated with improved pro-
tective immunity by focusing on popula-
tions associated with the accumulation
of activated antigen-specific T cells at
tumor beds. This analysis produced
only a significant association with a
group (genus) of bacteria termed Bifido-
bacterium. In the absence of antibiotic
depletion, administration of a cocktail of
Bifidobacterium species, or individual
Bifidobacterium species, through oral
gavage delayed tumor growth by boost-
ing tumor-specific T cell responses. Sup-
porting previous reports (Rutkowski et al.,
2015), and in agreement with the associa-
tion between enhanced integrity of the
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tective immunity (Ve´tizou et al., 2015), su-
perior anti-tumor immunity was not the
result of bacterial translocation. Although
the ultimate mechanism driving T-cell-
mediated anti-tumor immunity upon Bifi-
dobacterium expansion remains unclear,
the authors identified increased fre-
quencies of MHC-IIhigh DCs showing
markers of activation at tumor beds.
Together, these studies open new ave-
nues for modulating the composition of
the microbiota with either beneficial or
deleterious bacterial strains with the goal
of boosting anti-tumor immunity. Just as
importantly, they also offer new mecha-
nistic insight into why certain checkpoint
inhibitors or other immunotherapies
have variable effects in individuals with
cancer. Considering the organizational
complexity of commensal microorgan-
isms, however, the fact that adding Bifi-
dobacterium without antibiotic depletion
significantly influenced tumor growth in
the study by Sivan and colleagues comes
as a surprise. A possible explanation
could be that Bifidobacterium species
secrete antimicrobial substances that
alter the intestinal ecosystem (Buffie and
Pamer, 2013). For instance, it has been
shown that administration of Bifidobacte-
rium reduces intestinal inflammation in
models of colitis and causes a concomi-
tant decrease in Enterobacteriaceae
(Veiga et al., 2010). Surprisingly, changes
in enteric microflora after the administra-
tion of Bifidobacterium did not recapitu-
late the differences observed in Taconic
mice after gavage with Jackson feces.
Because it has been independently re-
ported that the enteric microflora of
Taconic mice harbors more Th17-cell-
promoting SFBs (Ivanov et al., 2009), a
logical hypothesis could have been thata decrease in SFBs, associated with
ameliorated IL-17 (tumor-promoting) re-
sponses, contributed to enhanced immu-
notherapeutic effectiveness. In fact, Bifi-
dobacterium-fed Taconic mice indeed
experienced a decrease in Candidatus
Arthromitus (formerly classified as a SFB
in mice), along with other related bacterial
families (e.g., Clostridiales). Unexpect-
edly, 16S ribosomal RNA-sequencing
analysis showed no differences in the
relative abundance of SFBs in fecal mate-
rials between mice newly arrived from
Taconic and those from Jackson Labora-
tory. Because these and other changes
were not found in Taconic mice fed with
Jackson fecal materials, Sivan and col-
leagues conclude that modulation of
the abundance of these or different bacte-
ria (e.g., tolerogenic butyrate-producing
species) is an unlikely contributor to supe-
rior protective immunity. This is an impor-
tant issue that needs to be reconciled with
previously established SFB expansion in
Taconic versus Jackson mice.
For both studies, a major question that
remains open is the relevance of these
findings for improving the effectiveness
of emerging immunotherapies by modu-
lating the composition of the microbiome
in cancer patients. Compared to humans,
mice have smaller and more homoge-
neous repertoires of commensal bacteria,
given that inbred strains have similar di-
ets, ages, and phenotypes. The clinical
data in the study of Ve´tizou and col-
leagues are particularly important in that
regard because they provide seminal in-
formation supporting the feasibility of
translating this approach. If individual
antibiotics can induce significant changes
in malignant progression and immune-
mediated therapeutic effectiveness (as
they have been elegantly shown to do inImmunity 43, Demice), studies to determine how either
combinations of selected antibiotics or
oral enrichment with specific commensal
bacteria synergizes in patients treated
with various immunotherapies are ur-
gently needed.REFERENCES
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